NeuroBo Pharmaceuticals (NRBO) Projected to Post Earnings on Thursday

NeuroBo Pharmaceuticals (NASDAQ:NRBO) is expected to issue its quarterly earnings data on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.89) per share for the quarter.

NeuroBo Pharmaceuticals Trading Up 1.9 %

Shares of NRBO stock opened at $1.58 on Wednesday. The firm has a 50-day moving average of $1.69 and a 200-day moving average of $2.27. NeuroBo Pharmaceuticals has a one year low of $2.08 and a one year high of $5.30.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity.